ストックスクリーナーアプリを入手
42.88
4.25%
1.75
アフターアワーズ：
42.90
0.02
+0.05%
Sionna Therapeutics Inc (SION) 最新ニュース
Stifel reiterates Buy on Sionna Therapeutics stock ahead of data By Investing.com - Investing.com Canada
Citizens reiterates Sionna Therapeutics stock rating on CF treatment potential By Investing.com - Investing.com Canada
Number of shareholders of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
A Quick Look at Today's Ratings for Sionna Therapeutics(SION.US), With a Forecast Between $50 to $63 - Moomoo
Freedom Broker downgrades Sionna Therapeutics (SION) - MSN
SION: Phase II data for two NBD1 stabilizers in CF expected this summer, aiming for superior efficacy - TradingView
Sionna Therapeutics Cut to Hold From Buy by Freedom Broker - Moomoo
Sionna Therapeutics Price Target Maintained With a $38.00/Share by Freedom Broker - Moomoo
Sionna Therapeutics stock rating cut to Hold at Freedom Broker By Investing.com - Investing.com Canada
SION Maintained by Stifel -- Price Target Raised to $55 - GuruFocus
Sionna Therapeutics Price Target Raised to $55.00/Share From $44.00 by Stifel - Moomoo
Wedbush Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $53 - Moomoo
Stifel raises Sionna Therapeutics price target on NBD1 data confidence By Investing.com - Investing.com Canada
User - FinancialContent
Wedbush initiates coverage of Sionna Therapeutics (SION) with outperform recommendation - MSN
Sionna Therapeutics, Inc. $SION Shares Purchased by Vanguard Group Inc. - MarketBeat
RBC Capital Sticks to Its Sell Rating for Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Sionna Therapeutics Develops Next-Generation Cystic Fibrosis Modulators - HarianBasis.co
Wedbush Initiates Coverage of Sionna Therapeutics (SION) - Insider Monkey
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Yazdi Reiterates Buy on Sionna, Keeps $58 Price Target Ahead of High-Impact 2026 SION-719 Readout - TipRanks
LifeSci Capital Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Sionna Therapeutics Q1 Net Loss Narrows - Moomoo
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 10.4% on Disappointing Earnings - MarketBeat
Guggenheim reiterates Sionna Therapeutics stock rating at Buy By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Sionna stock ahead of summer data - Investing.com
Wedbush reiterates Sionna Therapeutics stock rating on trial timelines - Investing.com
Sector Update: Healthcare - Moomoo
Wedbush reiterates Sionna Therapeutics stock rating on trial timelines By Investing.com - Investing.com Canada
Sector Update: Healthcare Stocks Advance Premarket Tuesday - Moomoo
Sionna Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sionna Therapeutics Reports Q1 2026 Financial Results and Completes Enrollment in PreciSION CF Phase 2a Trial - Minichart
Sionna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Sionna Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Earnings Flash (SION) Sionna Therapeutics Posts Q1 Net Loss $0.60 a Share, vs. FactSet Est of $0.54 Loss - marketscreener.com
Sionna Therapeutics 1Q 2026: Revenue ($27.4M), Net income ($26.78M), EPS ($0.6) — 10-Q Summary - TradingView
Earnings Flash (SION) Sionna Therapeutics Posts Q1 Net Loss $0.60 a Share, Vs. FactSet Est of $0.54 Loss - Moomoo
Sionna Therapeutics Reports First Quarter 2026 Financial Results - The Manila Times
Sionna Therapeutics 1Q Loss/Shr 60c >SION - Moomoo
Two cystic fibrosis trials with summer data expected as Sionna holds $289.9M cash - Stock Titan
Sionna Therapeutics stock hits all-time high at 46.65 USD By Investing.com - Investing.com India
Sionna Therapeutics Insider Sold Shares Worth $13,364,065, According to a Recent SEC Filing - Moomoo
Sionna Therapeutics(SION.US) Director Sells US$13.36 Million in Common Stock - Moomoo
OrbiMed Advisors LLC sells $13.3 million of Sionna Therapeutics (SION) stock - Investing.com UK
Sionna Therapeutics director Peter Thompson sells $13.36m in stock - Investing.com
OrbiMed Advisors LLC sells $13.3 million of Sionna Therapeutics (SION) stock By Investing.com - Investing.com Australia
Sionna Therapeutics director Peter Thompson sells $13.36m in stock By Investing.com - Investing.com Canada
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):